文献速递白血病

用于增强急性髓系白血病生存预测的4基因预后指数

A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
PubMed 文献 · Br J Haematol · 2024-04-23

研究基于五个队列975例非急性早幼粒细胞白血病化疗治疗的急性髓系白血病患者转录组,构建了包含CYP2E1、DHCR7、IL2RA和SQLE的4基因预后指数(4-PI),并在三个队列671例患者中验证其可重复性和临床效用,4-PI高分组富集TP53突变和胆固醇生物合成特征,单细胞RNA测序显示高4-PI细胞富集白血病干细胞特征,与56个现有预后指数比较显示4-PI性能更优,并可将ELN2017中危组患者重分类为高危组。

要点

  • 4-PI由CYP2E1、DHCR7、IL2RA和SQLE四个基因组成,可有效分层AML患者风险。
  • 高4-PI组富集TP53突变、胆固醇生物合成特征及白血病干细胞特征。
  • 4-PI在三个验证队列(含儿童AML)中显示可重复性,且可用实时定量PCR等低成本技术检测。

核心结论

  • 4-PI是一种稳健且简便的预后工具,可改善AML患者的生存预测。

研究设计与样本

  • 研究评估了五个队列975例非急性早幼粒细胞白血病化疗治疗的AML患者的转录组,以构建4-PI。
  • 在三个队列671例患者(包括一个儿童AML队列)中验证4-PI的可重复性和临床效用。
  • 与56个现有预后指数进行比较分析。

主要发现

  • 4-PI有效将患者分为风险类别,高4-PI组表现出TP53突变和胆固醇生物合成特征。
  • 单细胞RNA测序显示高4-PI细胞中富集白血病干细胞特征。
  • 验证显示4-PI具有可重复性和临床效用,甚至可使用实时定量聚合酶链反应等成本效益技术。
  • 与56个现有预后指数比较,4-PI表现更优。
  • 4-PI可将ELN2017中危组患者重分类为高危组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite advancements in utilizing genetic markers to enhance acute myeloid leukaemia (AML) outcome prediction, significant disease heterogeneity persists, hindering clinical management. To refine survival predictions, we assessed the transcriptome of non-acute promyelocytic leukaemia chemotherapy-treated AML patients from five cohorts (n = 975). This led to the identification of a 4-gene prognostic index (4-PI) comprising CYP2E1, DHCR7, IL2RA and SQLE. The 4-PI effectively stratified patients into risk categories, with the high 4-PI group exhibiting TP53 mutations and cholesterol biosynthesis signatures. Single-cell RNA sequencing revealed enrichment for leukaemia stem cell signatures in high 4-PI cells. Validation across three cohorts (n = 671), including one with childhood AML, demonstrated the reproducibility and clinical utility of the 4-PI, even using cost-effective techniques like real-time quantitative polymerase chain reaction. Comparative analysis with 56 established prognostic indexes revealed the superior performance of the 4-PI, highlighting its potential to enhance AML risk stratification. Finally, the 4-PI demonstrated to be potential marker to reclassified patients from the intermediate ELN2017 category to the adverse category. In conclusion, the 4-PI emerges as a robust and straightforward prognostic tool to improve survival prediction in AML patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Ortiz Rojas CA, Pereira-Martins DA, Bellido More CC, et al. A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction. Br J Haematol. 2024. PMID: 38651345. doi:10.1111/bjh.19472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。